Using systematic video analysis, researchers assessed the efficacy of nelotanserin for symptomatic treatment of REM sleep behavior disorder in patients with dementia.
Patients with Lewy body dementia with likely AD-type copathology may have impaired language compared to those without such copathology.
The FDA has granted Fast Track designation to neflamapimod (EIP Pharma) for the treatment of dementia with Lewy bodies (DLB).
A number of psychiatric and neurodegenerative diseases are associated with abnormal imaging findings, which can help psychiatrists reach a diagnosis.
There were no significant differences between pimavanserin and quetiapine in time to discontinuation, mortality, or improvement in psychosis in patients with Parkinson disease and Lewy body dementia.
Several prodromal symptoms in REM sleep behavior disorder are highly associated with conversion to neurodegenerative diseases.
Zonisamide as an adjunct to levodopa therapy improves parkinsonism in patients with dementia with Lewy bodies.
While parkinsonian disorders share a common mechanism of protein aggregation, manifestations are quite varied.
Patients with multiple system atrophy with parkinsonism face the greatest risk for death among synucleinopathies.
Increasing severity of AD pathology inversely correlated to decreases in time from motor symptoms to dementia onset and death.
